State of Wyoming Has $1.57 Million Stake in Illumina, Inc. $ILMN

State of Wyoming lowered its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 33.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,751 shares of the life sciences company’s stock after selling 6,374 shares during the period. State of Wyoming’s holdings in Illumina were worth $1,572,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Elyxium Wealth LLC bought a new position in Illumina during the fourth quarter valued at approximately $25,000. Creative Capital Management Investments LLC lifted its position in Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 120 shares during the period. TD Waterhouse Canada Inc. acquired a new position in Illumina in the 4th quarter worth approximately $26,000. Laurel Wealth Advisors LLC acquired a new position in shares of Illumina in the 4th quarter valued at about $26,000. Finally, Activest Wealth Management lifted its stake in shares of Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 215 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Performance

Shares of ILMN opened at $190.87 on Thursday. The company has a market cap of $28.88 billion, a PE ratio of 34.70, a price-to-earnings-growth ratio of 2.84 and a beta of 1.47. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm has a 50-day moving average of $169.14 and a 200-day moving average of $144.62. Illumina, Inc. has a one year low of $88.00 and a one year high of $196.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts forecast that Illumina, Inc. will post 5.22 earnings per share for the current year.

Insider Transactions at Illumina

In related news, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the transaction, the director owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. The trade was a 7.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Patricia Leckman sold 783 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ILMN has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upgraded shares of Illumina from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $125.00 to $185.00 in a report on Wednesday, June 10th. Royal Bank Of Canada began coverage on Illumina in a research report on Thursday, May 14th. They set an “outperform” rating and a $170.00 price target for the company. Guggenheim boosted their price target on Illumina from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Piper Sandler increased their price objective on shares of Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 1st. Finally, TD Cowen reissued a “hold” rating on shares of Illumina in a research note on Wednesday, July 15th. Nine equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $156.88.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.